Keywords: Shire, Adderall XR, Citizen petition, USA, FDA, Actavis, Watson Pharma, ANDA approval

Shire to face generic competition for Adderall XR from Actavis

Article | 25 June 2012

Print This

Shares in UK drugmaker Shire (LSE: SHP) fell around 9% to £17.82 in early trading this morning, after the company revealed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in